Response Biomedical receives patent for RAMP technology

Response Biomedical Corporation, based in Vancouver, British Columbia, has received a notice of allowance on its patent application connected to RAMP technology, which will be used for its tests in the biodefense industries.

The notice of allowance was issued by the United States Patent and Trademark Office for the “Comparative Multiple Analyte Immunoassay” patent. The patent is expected to be issued in the first quarter of 2011.

“We are pleased to see this patent issued in the U.S.,” Dr. Paul Harris, chief scientific officer for Response Biomedical, said. “The patent will allow the company to use the RAMP method to measure the relative amounts of two or more analytes with much more accuracy, than if the analytes were first measured and then the amounts compared. This increased accuracy is the result of not having to have standard curves. Instead the amounts are compared directly to each other.”

The RAMP platform is currently being used in clinical trials for the detection of congestive heart failure and heart attack and in the non-clinical market to detect West Nile Virus, smallpox, botulinum toxin, anthrax and ricin.

“As we focus on building our cardiac business in the U.S. and abroad, these patents further strengthen the compelling offering to our growing customer base,” S. Wayne Kay, Response Biomedical's CEO, said. “This patent also further builds on our solid and growing patent protection surrounding our innovative RAMP technology program.”